17:I[66739,["/_next/static/chunks/0.3dg.jzl0xwf.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/0skdv12y78fnh.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/10dnvbzcepzg2.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/0w-9dtq49e_fk.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/1331nw5i_3lcb.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/053zyoym-_i67.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8"],"default"] 19:I[38632,["/_next/static/chunks/0qqtp3r0h7kah.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8","/_next/static/chunks/0iukvycbd42rl.js?dpl=dpl_Hst3gh7MhZkzS6iaknkgT6LpsCH8"],"IconMark"] 18:T46b,

In this episode of Denatured, you'll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We examine how recessive dystrophic epidermolysis bullosa serves as a model for cell and gene therapy, and what this ultra-rare disease teaches us about scaling advanced treatments for the future.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Mark Lowdell, CSO & Co-Founder, INmuneBio Inc

Vishwas Seshadri, CEO & Director, Abeona Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

From fragile skin to living medicine: Lessons from RDEB

BioSpace

From fragile skin to living medicine: Lessons from RDEB